Header Logo

A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.

Yazici Y, Tambiah JRS, Swearingen CJ, Britt J, Kennedy S, Fineman MS, Simsek I, Solomon E, McAlindon TE. A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis. Clin Exp Rheumatol. 2025 May; 43(5):854-860.

View in: PubMed